胸腺肽、胸腺五肽、胸腺法新之间的区别,应如何选择?
2022-03-02 MedSci原创 MedSci原创
对于自身免疫力低下的癌症患者来说,胸腺肽、胸腺五肽、胸腺法新则成了提高免疫力的有力武器。
-
安全性、有效性
-
药理作用
-
用法用量
-
价格,注意事项等等
-
Placebo: 安慰剂
-
Thymosinalpha 1:胸腺法新
-
SQ:皮下注射
-
BIW:每周两次
-
Mos: 月
-
Responserate:定义为在12 个月随访时 HBV DNA 和 HBeAg 阴性的受试者的百分比
-
建议剂量:当用作单一疗法或与干扰素联合使用时,用于慢性乙型肝炎的ZADAXIN(胸腺嘧啶)的推荐剂量为1.6mg(900μg/m2),每周两次皮下给药,持续6至12个月。体重小于40 kg 的患者应接受40 μg/kg 的胸腺法新剂量。
-
Placebo:安慰剂
-
Thymosinalpha 1:胸腺法新
-
SQ:皮下注射
-
Qd: 一日一次
-
BIW:每周两次
-
TIW:每周三次
-
Mos: 月
-
Responserate:定义为在12 个月随访时 HBV DNA 和 HBeAg 阴性的受试者的百分比
-
Placebo:安慰剂
-
Thymosinalpha 1:胸腺法新
-
Ifosfamide: 异环磷酰胺
-
Dacarbazine:达卡巴嗪
-
SQ:皮下注射
-
BIW:每周两次
-
TIW:每周三次
-
Mos: 月
-
Responserate:定义为在12 个月随访时 HBV DNA 和 HBeAg 阴性的受试者的百分比
-
TACE: 一种破坏肿瘤的技术,其中将管子引导到肿瘤的动脉血液供应中,并引入药物,肌肉碎片或合成球体以阻塞动脉。
-
radiationtherapy:放疗
-
diseaseprogression:疾病进展
-
Follow- up:随访
-
建议剂量:用于癌症的日达仙(ZADAXIN)的推荐剂量为1.6mg(900μg/ m2),皮下注射6个月,或在治疗期间在化疗周期之间给予。
参考文献:
1. Mutchnick, M.G., Cummings, G.D.,Hoofnagle, J.H., and D.A. Shafritz (1992) Thymosin: An innovativeapproach to the treatment of chronic hepatitis B, in Combinationtherapies BiologicalResponse Modifiers in the Treatment ofCancer and Infectious Diseases, A.L Goldstein and E. Garaci, Editors. PlenumPublishing Corp: New York. p. 149-156
2. Mutchnick, M.G., Lindsay, K.L.,Schiff, E.R., Cummings, G.D., and H.D. Appelman (1995) Thymosin alpha 1treatment of chronic hepatitis B: a multicenter, randomized, placebo-controlleddouble blind
study Gastroenterology 108(4): p. A1127
3. Lee, S.-D., D.-S. Chen, and Y.-F. Liaw(1997) Multicenter Study of Thymosin Alpha 1 in the Treatment ofChronic Hepatitis B. Data on file.
4. Chien, R.-N., Liaw Y.-F., Chen, T.-C,Yeh, C.-T., and I.-S. Sheen (1998) Efficacy of Thymosin α1 in Patientswith Chronic Hepatitis B: A Randomized, Controlled TrialHepatology 27 (5) May 1998: p.1383-1387.
5. Niedzwiecki, D., Luo, D., Finn, D.S.,Whiting, G.W., Connelly, J.E., Kumashiro, M., Allen, I.E. and S.D. Ross(1997) The efficacy of thymosin alpha 1 in chronic hepatitis B: ameta-analysis, Data on file.
6. Sherman, K.E., Sjogren, M., Greager, R.L.Damiano, M.A., Freeman, S., Lewey, S. Davis, D., Root, S., Weber, F.L., IshakK.G., and Z.D. Goodman (1998) Combination Therapy with Thymosin alpha 1and Interferon for the Treatment of Chronic Hepatitis C Infection: ARandomized, Placebo-Controlled Double-Blind Trial, Hepatology 27 (4):p. 1128-1135
7. Rasi, G., DiVirgilio, D., Mutchnick,M.G., Colella, F, Sinibaldi-Vallebona, P., Pierimarchi, P. Balli, B., and E.Garaci (1996) Combination thymosin α1 and lymphoblastoid interferontreatment in chronic hepatitis C, Gut 39: p. 679-683.
8. Moscarella, S ., Buzzelli, G., MontiM., Giannini, C, Careccia, G. Marrochi, E.M., Romanelli, R.G. and A.L. Zignego(1997) Treatment with interferon-alpha and thymosin alpha 1 of naivepatients affected by chronic hepatitis C, in 4th International meetingon HepatitisC Virus and Related Viruses. Kyoto, Japan
9. Sherman, K.E., and S.N. Sherman(1997) Pooled analysis of interferon + thymosin alpha-1 efficacy forthe treatment of chronic hepatitis C. Second International Conferenceon Therapies for ViralHepatitis, Kona, Big Island Hawaii, December15-19: abstract #P50
10. Stefanini, G.F., et al., Alpha-1 thymosin and transcatheter arterial chemoembolization in hepatocellularcarcinoma patients: a preliminary experienceHepatogastroenterology, 1988. 45 (19): p.209-215
11. Schulof, R.S., et al., A randomizedtrial to evaluate the immunorestorative properties of synthetic thymosin alpha1 in patients with lungcancer. Journal of Biological ResponseModifiers 1985 4: p. 147-158
12. Salvati, F, et al., Combinedtreatment with thymosin alpha 1 and low dose interferon-alpha after ifosfamidein non-smallcell lung cancer: a phase II controlledtrial. Anticancer Research 1996 16: p. 1001-1004
13. Rasi, G., Terzoli, E., lzzo, F., etal., Combined treatment with thymosin alpha 1 and low dose nterferon alphaafter dacarbazine in advanced melanoma. Melanoma Research 2000 10: p 189-192
14. Lopez, M, et al., Biochemotherapywith thymosin alpha 1, inteluken-2 and dacarbazine in patients with metastaticmelanoma: clinical and immunological effects. Annals of Oncology 1994 5: p. 741-746.
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
#胸腺#
62
以前只知道越来越贵哈哈
61
非常棒 受用了
72
学习
59